目的：比较连续4次玻璃体腔注射康柏西普与阿柏西普治疗湿性年龄相关性黄斑变性(wARMD)的临床疗效。

方法：回顾性分析2019-01/2021-01于我院确诊为wARMD并行玻璃体腔注射治疗的患者108例108眼的临床资料，依据注射药物不同分为康柏西普组(54例54眼)与阿柏西普组(54例54眼)，均接受玻璃体腔注射治疗，每月注射1次，连续注射4次。随访12mo，观察注药前后BCVA、CMT及注药后并发症和复发情况。

结果：注药后1、2、5、8mo两组患者BCVA和CMT均无组间差异(P>0.05)，但均较注药前显著改善(P<0.05)。至随访结束，康柏西普组早期发生结膜出血2眼，阿柏西普组则出现眼压增高和结膜出血各1眼，两组患者均未见视网膜脱离、并发性白内障、眼内炎及视网膜色素上皮撕裂等与注药相关的严重并发症发生，且两组间复发率比较无差异(7% vs 6%，P=1.000)。

结论：连续4次玻璃体腔注射康柏西普与阿柏西普均可安全有效地治疗wARMD，疗效均势。

METHODS: The clinical data of 108 patients(108 eyes)who were diagnosed as wARMD and treated with intravitreal injection at our hospital from January 2019 to January 2021 were retrospectively analyzed. They were divided into conbercept group(54 cases, 54 eyes)and aflibercept group(54 cases, 54 eyes)according to the different injectable drugs. All patients received intravitreal injection once a month, with four consecutive injections. Follow up for 12mo to observe best corrected visual acuity(BCVA), central macular thickness(CMT), complications and recurrence before and after injection.

RESULTS: BCVA and CMT of patients in the two groups at 1, 2, 5 and 8mo after injection had no between-group differences(P>0.05), but both were significantly improved compared with those before injection(P<0.05). By the end of follow-up, conjunctival hemorrhage occurred in 2 eyes of the conbercept group at the early stage, and increased intraocular pressure and conjunctival hemorrhage occurred respectively in 2 eyes of the aflibercept group. There were no serious complications related to drug injection such as retinal detachment, complicated cataract, endophthalmitis and retinal pigment epithelial tear in the two groups, and there was no difference in the recurrence rate between the two groups(7% vs. 6%, P=1.000).

CONCLUSION: On the basis of continuous 4 times of intravitreal injection, both conbercept and aflibercept are safe and effective in the treatment of wARMD, and the efficacy is even.